HRSA announced Oct. 1 that it has approved 10 drugmakers to participate in a revised 340B Rebate Model Pilot Program, which will replace the traditional upfront 340B discount with a post-sale rebate structure for a limited set of drugs starting…

Becker’s asked pharmacy executives from hospitals and health systems, along with academic medical centers and universities across the U.S. to share what trends they deem dangerous. The 14 executives featured in this article are all speaking at Becker’s Healthcare 3rd…

Arizona Attorney General Kris Mayes filed a consumer fraud lawsuit Oct. 1 against pharmacy benefit managers Express Scripts and Optum, alleging the companies’ formulary and rebate practices substantially contributed to the opioid epidemic in the state over more than two…

Medication management used to be pharmacy’s job. Increasingly, it’s an enterprise leadership issue — and health systems that still treat it as a departmental function are already behind. For most of my career, pharmacy leaders and clinical teams built the…

An October report from Berkeley Research Group estimates how much patients and payers spend on 340B drugs, beyond what covered entities pay to acquire them. Here are six findings to know:

Merck has stopped manufacturing and marketing Recarbrio, an antibiotic that targeted multidrug-resistant infections.  The FDA approved Recarbrio (cilastatin sodium, imipenem and relebactam) in July 2019 for adults with complicated urinary tract infections or complicated intra-abdominal infections who have limited or…

The FDA has approved Camzyos (mavacamten) capsules as the first treatment for children with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. Camzyos is now approved for adults and pediatric patients weighing at least 30 kilograms (approximately 66…

CMS has finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, a mandatory payment model that will tie Medicare Part B drug rebates to prices paid in 19 reference countries, according to a Sept. 30 CMS news release. Here…

The 100% Section 232 tariff on patented pharmaceuticals and associated pharmaceutical ingredients took full effect Sept. 29 for companies not already covered under the July 31 implementation date. The Commerce Department’s Bureau of Industry and Security has defined which specialty…

The Pharmaceutical Research and Manufacturers of America has named Eric Cantor its next president and CEO, effective Nov. 9. Mr. Cantor will succeed Stephen Ubl, who has led PhRMA since 2015, according to a Sept. 29 news release. Mr. Ubl…